A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

NCT00089869 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2006-07-20

No results posted yet for this study

Summary

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

Conditions

Interventions

DRUG

olanzapine

DRUG

atomoxetine

DRUG

placebo

Sponsors & Collaborators

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089869 on ClinicalTrials.gov